Literature DB >> 10672759

Alexithymic characteristics of HIV-positive patients.

I Fukunishi1, N Hirabayashi, T Matsumoto, K Yamanaka, K Fukutake.   

Abstract

Despite extensive psychiatric research on HIV-positive patients, there are no published studies on alexithymia. Alexithymic characteristics and related factors were examined in a sample of 81 HIV-positive patients using the modified Beth Israel Psychosomatic Questionnaire and the Social Support of Stress and Coping Inventory. The severity of alexithymia was significantly higher in HIV patients than healthy controls, suggesting the presence of secondary alexithymia. Scores on two alexithymic characteristics, affect awareness and operational thinking, significantly correlated with ratings of poor utilization and perception of social support. As the severity of HIV infection progressed, affect awareness was higher, controlling for poor utilization and perception of social support. These results suggest that secondary alexithymia, associated with poor utilization and perception of social support, may be manifest as a state reaction to approaching death.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10672759     DOI: 10.2466/pr0.1999.85.3.963

Source DB:  PubMed          Journal:  Psychol Rep        ISSN: 0033-2941


  3 in total

1.  Anterior Insula Activation During Cardiac Interoception Relates to Depressive Symptom Severity in HIV-Positive and HIV-Negative Postmenopausal Women.

Authors:  Roger C McIntosh; Judith D Lobo; Michael Reed; Jennifer C Britton
Journal:  Psychosom Med       Date:  2022-09-06       Impact factor: 3.864

2.  Neurocognitive correlates of alexithymia in asymptomatic individuals with HIV.

Authors:  Yelena Bogdanova; Mirella Díaz-Santos; Alice Cronin-Golomb
Journal:  Neuropsychologia       Date:  2009-12-28       Impact factor: 3.139

3.  Alexithymia: a general deficit of interoception.

Authors:  Rebecca Brewer; Richard Cook; Geoffrey Bird
Journal:  R Soc Open Sci       Date:  2016-10-12       Impact factor: 2.963

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.